Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Danielle Canioni, MD, Pauline Brice, MD, Serge Bologna, MD, Laurent Voillat, MD, Jean Gabarre, MD, Olivier Casasnovas, MD, Alain Devidas, MD, Bertrand Coiffier, MD PhD, Malek Aoudjhane, MD, Bruno Audhuy, MD, Marc Andre, MD, Catherine Fortpied, MD, Patrice Carde, MD PhD, Nicolas Mounier, MD, Josette Briere, MD

Blood (2018) 132 (Supplement 1): 4132.

https://doi.org/10.1182/blood-2018-99-118039

Published: 2018

Journal Articles

Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study

Blood (2018) 132 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2018-99-112874

Published: 2018

Journal Articles

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Blood (2018) 132 (Supplement 1): 1596.

https://doi.org/10.1182/blood-2018-99-110334

Published: 2018

Journal Articles

Similar Efficacy and Safety of CT-P10 and Reference Rituximab in Patients with Advanced Stage Follicular Lymphoma: Updated Phase III Study Results

Won-Seog Kim, MD PhD, Christian Buske, MD, Larry W Kwak, MD PhD, Michinori Ogura, MDPhD, Bertrand Coiffier, MD PhD, SangJoon Lee, PhD, SuYoung Kim

Blood (2018) 132 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2018-99-112716

Published: 2018

Journal Articles

Coinfection with HCV or HBV Increases the Risk of Lymphoma in HIV-Positive Patients: A Combined Analysis of the Lymphovir-ANRS-CO16 and Fhdh-ANRS-CO4 Cohorts

Blood (2017) 130 (Supplement 1): 1003.

https://doi.org/10.1182/blood.V130.Suppl_1.1003.1003

Published: 2017

Journal Articles

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

Blood (2017) 130 (Supplement 1): 486.

https://doi.org/10.1182/blood.V130.Suppl_1.486.486

Published: 2017

Journal Articles

Clinical Factors Impact on Pharmacokinetics of CT-P10 and Reference Rituximab in Patients with Advanced-Stage Follicular Lymphoma

Won Seog Kim, MD, Ph. D., Bertrand Coiffier, MD PhD, Christian Buske, MD, Michinori Ogura, MD PhD, Larry W Kwak, MDPhD, SangJoon Lee, YunJu Bae, SuYoung Kim, MinJu Kim, SangMi Lee, DaHye Kwak, HyunJin Lee

Blood (2017) 130 (Supplement 1): 1504.

https://doi.org/10.1182/blood.V130.Suppl_1.1504.1504

Published: 2017

Journal Articles

IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

Blood (2017) 130 (Supplement 1): 1506.

https://doi.org/10.1182/blood.V130.Suppl_1.1506.1506

Published: 2017

Journal Articles

A MALT lymphoma prognostic index

Catherine Thieblemont, Luciano Cascione, Annarita Conconi, Barbara Kiesewetter, Markus Raderer, Gianluca Gaidano, Maurizio Martelli, Daniele Laszlo, Bertrand Coiffier, Armando Lopez Guillermo, Valter Torri, Franco Cavalli, Peter W. Johnson, Emanuele Zucca

Blood (2017) 130 (12): 1409–1417.

https://doi.org/10.1182/blood-2017-03-771915

Published: 2017

Includes: Supplemental data

Journal Articles

Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area

Caroline Gay, Richard Delarue, Noel Milpied, Lucie Oberic, Bertrand Coiffier, Sami Boussetta, Corinne Haioun, Hervé Tilly, Gilles Salles, Thierry Lamy, Marie-Antoinette Lester, Roch Houot

Blood (2017) 129 (20): 2811–2813.

https://doi.org/10.1182/blood-2017-02-766147

Published: 2017

Includes: Supplemental data

Journal Articles

Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

Qian Shi, PhD, Norbert Schmitz, MD, PhD, Christopher Flowers, MD MS, Fang-Shu Ou, PhD, David Cunningham, Michael Pfreundschuh, MD, John F Seymour, Ulrich Jaeger, Thomas M. Habermann, MD, Corinne Haioun, MD PhD, Hervé Tilly, MD PhD, Herve Ghesquieres, MD PhD, Francesco Merli, Marita Ziepert, Raoul Herbrecht, MD, Jocelyne Flament, MD, Tommy Fu, PhD, Bertrand Coiffier, MD PhD, Daniel Sargent, PhD

Blood (2016) 128 (22): 4196.

https://doi.org/10.1182/blood.V128.22.4196.4196

Published: 2016

Journal Articles

First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa

Blood (2016) 128 (22): 471.

https://doi.org/10.1182/blood.V128.22.471.471

Published: 2016

Journal Articles

Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients

Blood (2016) 128 (22): 3027.

https://doi.org/10.1182/blood.V128.22.3027.3027

Published: 2016

Journal Articles

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

Bertrand Coiffier, Juan-Manuel Sancho, Wojciech Jurczak, Jin Seok Kim, Raj V Nagarkar, Edvard Zhavrid, Jose Angel Hernandez Rivas, Aliaksandr Prokharau, Mamia Zodelava, Dzhelil Osmanov, Michinori Ogura, Christian Buske, Larry Kwak, Sang Joon Lee, Sung Young Lee, Yun Ju Bae, Won Seog Kim

Blood (2016) 128 (22): 1807.

https://doi.org/10.1182/blood.V128.22.1807.1807

Published: 2016

Journal Articles

Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies

Aurelie Cabannes-Hamy, MD, Frederic Peyrade, MD, Fabrice Jardin, MD PhD, Jean-Francois Emile, Sylvie Castaigne, MD PhD, Bertrand Coiffier, MD PhD, Corinne Haioun, MD, Aurore Perrot, MD, Olivier Fitoussi, MD, Safia Chebrek, Christophe Fruchart, Julie Abraham, MD, Richard Delarue, MD, Marc Andre, MD, Gilles Salles, MD PhD, Philippe Gaulard, MD PhD, Herve Tilly, MD PhD, Catherine Thieblemont, MD PhD

Blood (2016) 128 (22): 927.

https://doi.org/10.1182/blood.V128.22.927.927

Published: 2016

Journal Articles

Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study

Vincent Ribrag, MD, Won Seog Kim, MD PhD, Reda Bouabdallah, MD, Soon Thye Lim, MBBS, MRCP, Bertrand Coiffier, Zakia Felloussi, Ioana Kloos, Ying Luan, PhD, Thorsten Graef, MD PhD, Franck Morschhauser, MD

Blood (2015) 126 (23): 256.

https://doi.org/10.1182/blood.V126.23.256.256

Published: 2015

Journal Articles

Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study

Blood (2015) 126 (23): 1472.

https://doi.org/10.1182/blood.V126.23.1472.1472

Published: 2015

Journal Articles

Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL)

Won Seog Kim, Michinori Ogura, Christian Buske, Bertrand Coiffier, Juan-Manuel Sancho, Wojciech Jurczak, Jin Seok Kim, Raj V Nagarkar, Edvard Zhavrid, Jose Angel Hernandez Rivas, Yuriy Vinnyk, Panagiotis Tsirigotis, Piera Viero, Elena Volodicheva, Samuel Fourie, Juan Soler

Blood (2015) 126 (23): 5111.

https://doi.org/10.1182/blood.V126.23.5111.5111

Published: 2015

Journal Articles

Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

Andrew D Zelenetz, MD, PhD, Tadeusz Robak, MD, PhD, Bertrand Coiffier, MD, PhD, Julio Delgado, MD, Paula Marlton, MBBS, Adeboye H Adewoye, MD, Yeonhee Kim, PhD, Lyndah K. Dreiling, MD, Peter Hillmen, MB, ChB, PhD

Blood (2015) 126 (23): LBA-5.

https://doi.org/10.1182/blood.V126.23.LBA-5.LBA-5

Published: 2015

Journal Articles

Pre-Phase Chemotherapy Followed By Ofatumumab (OFA) and Reduced Dose CHOP (OFA-mini-CHOP) for Patients over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – a Lymphoma Study Association (LYSA) Prospective Phase II Study (LNH09-7B)

Blood (2014) 124 (21): 3042.

https://doi.org/10.1182/blood.V124.21.3042.3042

Published: 2014

NARROW

Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Similar Efficacy and Safety of CT-P10 and Reference Rituximab in Patients with Advanced Stage Follicular Lymphoma: Updated Phase III Study Results

Coinfection with HCV or HBV Increases the Risk of Lymphoma in HIV-Positive Patients: A Combined Analysis of the Lymphovir-ANRS-CO16 and Fhdh-ANRS-CO4 Cohorts

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

Clinical Factors Impact on Pharmacokinetics of CT-P10 and Reference Rituximab in Patients with Advanced-Stage Follicular Lymphoma

IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

A MALT lymphoma prognostic index

Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area

Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies

Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study

Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study

Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL)

Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

Pre-Phase Chemotherapy Followed By Ofatumumab (OFA) and Reduced Dose CHOP (OFA-mini-CHOP) for Patients over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – a Lymphoma Study Association (LYSA) Prospective Phase II Study (LNH09-7B)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only